8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
REGENERON PHARMACEUTICALS, INC. (REGN)

Regeneron filed an 8‑K (Item 9.01) on Jan 30, 2026: Exhibit 99.1 = press release reporting Q4 & full‑year…

Filed with the SEC on · Summarized by InvestorsBot

Regeneron filed an 8‑K (Item 9.01) on Jan 30, 2026: Exhibit 99.1 = press release reporting Q4 & full‑year 2025 financial & operating results; Exhibit 104 = cover page XBRL. Signed by Joseph J. LaRosa. 📄 $REGN #earnings #biotech

Investor note: The 8‑K points to the press release with Q4 & FY2025 metrics — check Exhibit 99.1 and the XBRL Exhibit 104 for detailed revenue, guidance and ops data. Disclosure dated Jan 30, 2026. 📈 $REGN #pharma #earnings

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from REGENERON PHARMACEUTICALS, INC.

Regeneron ($REGN) issued a press release on Jan 30, 2026 announcing financial & operating results for the…

8-K · January 30, 2026

Regeneron filed an 8‑K (1/12/26) attaching Exhibit 99.1 — a Jan 12, 2026 presentation by CEO Leonard S.

8-K · January 12, 2026

Regeneron ($REGN) on 2026-01-12 furnished a Regulation FD presentation (Exhibit 99.1) referenced in Item…

8-K · January 12, 2026

Regeneron says Q4 2025 will include an acquired IPR&D charge of ~ $19M pre-tax, reducing GAAP and non‑GAAP…

8-K · January 12, 2026